Newbridge Financial Services Group’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
– Sell
-6,650
Closed -$2.39K – 1467
2023
Q1
$2.39K Hold
6,650
– – ﹤0.01% 1174
2022
Q4
$5.89K Hold
6,650
– – ﹤0.01% 1032
2022
Q3
$10K Hold
6,650
– – 0.01% 898
2022
Q2
$13K Hold
6,650
– – 0.01% 795
2022
Q1
$15K Sell
6,650
-750
-10% -$2.34K 0.01% 823
2021
Q4
$34K Sell
7,400
-12,925
-64% -$80.2K 0.02% 579
2021
Q3
$155K Buy
20,325
+2,275
+13% +$19.3K 0.1% 203
2021
Q2
$175K Buy
18,050
+1,000
+6% +$7.96K 0.11% 195
2021
Q1
$141K Sell
17,050
-5,500
-24% -$58.1K 0.1% 207
2020
Q4
$154K Sell
22,550
-4,350
-16% -$34.9K 0.13% 169
2020
Q3
$300K Buy
+26,900
New +$246K 0.3% 75

Other funds holding SRNE

Newbridge Financial Services Group's SRNE Position: Q2 2023 in Review

Newbridge Financial Services Group sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2023, closing a stake of 6,650 shares — an estimated $2.39K sold.

Newbridge Financial Services Group first reported a position in SRNE in Q3 2020 and held it in 11 quarters. The position peaked at $300K in Q3 2020. 9 funds tracked by Wall St. Rank hold SRNE as of Q2 2023.

  • Newbridge Financial Services Group reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2023 after selling out during the quarter.
  • Newbridge Financial Services Group sold 6,650 Sorrento Therapeutics, Inc. shares in Q2 2023, an estimated $2.39K.
  • Newbridge Financial Services Group first reported a position in Sorrento Therapeutics, Inc. in Q3 2020 and held it in 11 quarters.
  • Newbridge Financial Services Group's Sorrento Therapeutics, Inc. position peaked at $300K in Q3 2020.
  • 9 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2023.

Based on Newbridge Financial Services Group's 13F filing for Q2 2023, filed 21 Jul 2023.